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Stent graft repair in the aortic arch and descending
thoracic aorta: A 4-year experience
Frank J. Criado, MD, Nancy S. Clark, MD, and Marcos F. Barnatan, MD, Baltimore, Md
Background: Thoracic aortic aneurysms (TAAs) and type B aortic dissections (ADs) are relatively frequent, serious
conditions that are often managed nonoperatively because of perceived poor outcome of standard surgical reconstruction.
Recently developed stent graft techniques represent a more attractive, less invasive option. We sought to determine the
technical feasibility and safety of endovascular repair in the thoracic aorta with a retrospective review of our experience
with such an approach.
Methods: Forty-seven patients received thoracic stent graft implants during the 4-year period ending March 31, 2002. All
patients signed an Institutional Review Board–approved informed consent. Thirty-one patients had TAAs, and 16 had
ADs. Device design and implant strategy were on the basis of evaluation of morphology with angiography and computed
tomographic scan. The procedures were done with fluoroscopic guidance, with local anesthesia in five cases, spinal
anesthesia in 19 cases, and general anesthesia in 23 cases. Endovascular access was achieved with femoral cutdown in 41
cases and a temporary iliac conduit in six cases. A Talent patient-specific device, with 4-mm to 6-mm oversize, was used
in all. Proximal endograft attachment was in the descending thoracic aorta in 16 cases, parasubclavian in 21 cases, and the
suprasubclavian aorta in 10 cases. Eight patients had adjunctive cervical reconstruction to transpose or revascularize the
left subclavian or left common carotid arteries, enabling more proximal endograft attachment in the aortic arch.
Results: Access failure occurred in one patient (2.1%). One patient (2.1%) died within 30 days of access-related iliac artery
rupture. Another death occurred at 60 days from a ruptured thoracoabdominal aneurysm with type I endoleak. No
instances of paraplegia, stroke, or surgical conversion were seen. Five patients (TAA) were found to have endoleak on
30-day computed tomographic scan. Repair of type I endoleak was undertaken in three cases at 1, 4, and 6 months. Eight
patients (17%) had adverse events within the first 30 days. Length of follow-up ranged from 1 to 44 months, with a mean
of 18 months. Two patients were lost to follow-up, and one withdrew from the study. Four additional mortalities were
observed, none related to the endograft or aortic pathology.
Conclusion: Stent graft repair of TAA and AD is feasible and can be achieved with technical success and relatively low rates
of perioperative morbidity and mortality. The Talent customized design proved versatile in various morphologies. More
information is needed on indications, clinical efficacy, and long-term results. (J Vasc Surg 2002;36:1121-8.)
Management of patients with thoracic aortic pathology
represents a continuing formidable challenge. Aneurysms
and acute dissections occur with considerable frequency.
The estimated yearly incidence rate of thoracic aortic aneu-
rysms (TAAs) is six cases per 100,000,1-3 and acute aortic
dissection (AD) is said to affect 10 to 20 individuals per
million population.4,5 Until recently, the only effective
treatment method was surgical graft replacement, involving
rather morbid and at times technically complex operations.
Transthoracic aortic surgery carries substantial risks of seri-
ous complications and mortality, which have diminished
only slightly in recent years in spite of significant advances
in perioperative care and surgical techniques.6-9 The result
is that many, perhaps most patients, are managed with
“benign neglect” or “observation only” because surgeons
are reluctant to undertake operative reconstruction. Endo-
vascular stent graft repair is an innovative, less invasive
treatment method based on the principle of segmental
exclusion with an endoluminal prosthesis.9-11 This report
presents the results of a review of our 4-year clinical expe-
rience with treatment of TAA and type B AD with custom-
ized Talent stent grafts (Medtronic AVE, Santa Rosa,
Calif).
METHODS
Forty-seven patients received thoracic stent graft im-
plants during the 4-year period ending March 31, 2002.
They represent 76% of 62 patients referred to the senior
author (FJC) for possible endovascular repair during the
same time interval. The 15 patients excluded from consid-
eration of endovascular treatment had small or diseased
access iliac arteries (n  9) or extensive aneurysmal disease
without identifiable “landing zones” for endograft attach-
ment and seal (n  6). Eighty percent of the patients were
referred by cardiac or vascular surgeons after operative
intervention was ruled out. All patients signed an Institu-
tional Review Board–approved informed consent and were
made fully aware of the investigational nature of endovas-
cular treatment. Thirty-one patients had TAA, and 16 had
type B AD. Aneurysms were considered for repair when one
or more of the following were present: symptoms (pain),
maximum diameter of the sac more than 5.0 cm, or more
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than twice the diameter of an adjacent nonaneurysmal
segment of the thoracic aorta. Of the patients with treated
TAA, only three had aneurysms of less than 6.0 cm. The
indications for intervention in AD cases related to one or
more of the following findings: continuing pain despite
“optimal” medical management, evidence or suspicion of
aortic branch or lower extremity ischemia, and hemotho-
rax. Two patients with AD (undergoing stent graft inter-
vention) did not have a clinical imperative for intervention
but were found to have a markedly compressed true lumen
on computed tomography (CT; true/false lumen ratio,
0.1). Risk stratification with The Society for Vascular
Surgery/International Society for Cardiovascular Surgery
scoring12 placed 40 patients (85%) in the 2 to 3 categories
and seven in the 0 to 1.
Device design and implant strategy were on the basis of
evaluation of morphology with catheter angiography and
3-mm slice contrast-enhanced spiral CT scan. Patient char-
acteristics and morphology are summarized in Tables I and
II. Local anesthesia was used in five procedures, spinal in
19, and general in 23. The procedures were done in the
operating room with fluoroscopic guidance. The anesthe-
siologist was asked to control the blood pressure pharma-
cologically if necessary, maintaining the mean at 80 mm Hg
or lower. Stent graft placement for aneurysms was designed
to cover the length of the lesion and extend (if possible) 20
mm proximally and distally beyond the aneurysm. The
strategy for treatment of AD involved endograft coverage
of the entry site to redirect blood flow down the true lumen
exclusively; it also extended 20 mm in either direction if
anatomically possible. Endoluminal access was achieved
with single-groin femoral cutdown in 41 instances and a
temporary iliac conduit in six instances. A diagnostic pigtail
catheter was used in all cases, transfemoral in 13 and
transbrachial in 34. With exchange technique under fluo-
roscopy, an extra stiff (Lunderquist, Cook, Inc, Blooming-
ton, Ind) guidewire was inserted retrograde to the level of
the proximal ascending aorta. Such stiff wire provided the
necessary support for advancement and deployment of the
stent graft system. The device used on all patients was the
Medtronic Talent patient-specific self-expanding en-
dograft, with a 4-mm to 6-mm diameter oversize. It incor-
porated an uncovered proximal stent (bare spring) for
transostial placement with preservation of branch-artery
patency (Fig 1). Configuration was single segment in 29
cases, two overlapping segments in 15 cases, and three or
more in three cases. The Talent thoracic delivery system
used in this experience was relatively stiff, which repre-
sented a technical challenge at the time of deployment
when the delivery sheath was bent across the full length of
the aortic arch. In some of these cases, to facilitate stent
graft deployment, sheath pull-back (partially uncovering
the balloon situated just ahead of the graft) was initiated
while the system lay straight in the descending thoracic
aorta (DTA), with subsequent readvancement across the
aortic arch. Although these maneuvers proved at times
difficult, and potentially troublesome because of the partial
“break” in sheath profile, no apparent complications could
be attributed to them. Proximal endograft attachment was
in the DTA more than 2 cm distal to the origin of the left
subclavian artery (LSA) in 16 cases, within 2.0 cm of the
LSA (the parasubclavian aorta) in 21 cases, and proximal to
the LSA in 10 cases (Fig 2). The endograft was placed
across the origin of the LSA (without revascularization) in
five instances (Fig 3). Eight patients had one (n 7) or two
(n 1) preliminary adjunctive cervical operations designed
to disconnect and revascularize the LSA or the left common
carotid artery to enable stent graft placement in the more
proximal aortic arch (Figs 4 to 6). Distal stent graft attach-
ment was in the supradiaphragmatic DTA in 43 cases and
within the proximal abdominal aorta in four. Among the
latter, the celiac artery origin was crossed with the uncov-
ered stent in two cases and intentionally occluded (covered)
by the endograft in one case. Adjunctive techniques to
prevent paraplegia (ie, spinal fluid drainage) were not used
in any case during this experience.
RESULTS
One procedure (2.1%) was aborted because of access
failure. One patient (2.1%) died intraoperatively of access-
related iliac artery rupture causing massive hemorrhage; a
second patient had a similar rupture that could be repaired
successfully with an endoluminal graft. Procedure time
ranged from 25 to 174 minutes, with a mean of 110
minutes. There were no additional 30-day mortalities, but
one other death occurred at 60 days from a ruptured and
infected thoracoabdominal aneurysm with juxtaceliac at-
tachment-site endoleak. This was the case of a patient with
a large symptomatic thoracoabdominal aneurysm whose
condition was deemed inoperable because of medical co-
morbidities. The distal neck for stent graft attachment was
inadequate (1.0 cm), necessitating crossing of the celiac
trunk with the device’s bare spring. Although aneurysm
exclusion was achieved initially, it proved short lived, with
subsequent development of a high-pressure type 1 en-
doleak, which eventually caused the fatal rupture. Infection
Table I. TAA cases (n  31)
Male, 19; female, 12
Age range, 37 to 88 y; mean, 74 y
Significant comorbidities, 19/31 (61%)
High surgical risk or “inoperable,” 24/31 (77%)
Aneurysm size, 4.8 to 10.7 cm; mean, 6.8 cm
Table II. Aortic dissection cases (n  16)
Male, 14; female, 2
Age range, 33 to 68 y; mean, 56 y
Hypertension, 14/16 (87%)
Interval from Dx to Rx, 2 to 16 d; mean, 6.5 d
False lumen patent, 14/16 (87%)
Distal extent: renal, 3; infrarenal aorta, 2; iliac, 11 (68%)
Contained rupture, 2
Marked compression of true lumen,12/16 (75%)
Dx, Diagnosis; Rx, treatment.
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(with grossly purulent material within the aneurysm sac)
was an unexpected additional finding at autopsy. No pa-
tient had paraplegia or stroke develop, and there were no
surgical conversions.
Eight patients (17%) had nonfatal morbid adverse
events within the first 30 days. These involved femoral
wound hematoma necessitating surgical evacuation (n 
1), access-site femoral artery thrombosis that was treated
with surgical thrombectomy and endarterectomy/patch
angioplasty (n  1), respiratory complications prolonging
hospitalization (n 3), non–Q wave myocardial infarction
(n  1), “postimplant syndrome” with severe back pain,
fever, and leukocytosis lasting several days (n  1), and
lymph leakage from a cervical incision after a preliminary
subclavian-to-carotid transposition (n  1). Three addi-
tional reoperations were performed for secondary endovas-
cular repair of attachment-site (type 1) endoleak at 1, 4, and
6 months . The procedures involved placement of one (n
2) or two (n  1) additional stent graft segments, with
successful resolution of endoleak. In total, five patients
were shown to have endoleak on the 30-day contrast CT
scan; they all underwent further evaluation with catheter
angiography, which showed a type 1 endoleak in three cases
and no contrast extravasation in two cases. All three pa-
tients with type 1 endoleak underwent secondary endovas-
cular repair (as described previously). The other two pa-
tients were (and continue to be) observed; the CT scan–
detected endoleaks have resolved in one case (after 2
months) and persisted in another. Both patients’ thoracic
Fig 1. A, Talent thoracic stent graft. B, Contrast-enhanced spiral CT scan shows acute type B AD with ongoing
extravasation of contrast (circle) and huge left hemothorax (asterisk). Talent stent graft placement (right), with crossing
of LSA origin with uncovered stent. Note diagnostic pigtail catheter in LSA.
Fig 2. Aortic arch map contains five zones to describe and docu-
ment proximal endograft attachment.
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aneurysms have remained stable, without further enlarge-
ment. Of the 16 cases of AD (n  16), the false lumen
became completely thrombosed after stent graft placement
in 10 of 14 (71%) and only partially thrombosed in four.
False-lumen thrombosis was noted in two patients before
surgery.
Length of follow-up ranged from 1 to 44 months, with
a mean of 18 months. Two patients were lost to follow-up,
and one withdrew from the study. Patient surveillance
involved contrast/noncontrast CT scan and plain-film ra-
diographs of the stent graft device at 6-month intervals.
Device migration and metal-frame integrity were assessed,
Fig 3. A, Huge aneurysm (8.5 cm) of aberrant right subclavian artery, with aneurysmal involvement of proximal LSA.
B, Stent graft exclusion of right subclavian artery and LSA, with filling of LSA via retrograde flow from left vertebral.
C, Angiographic result, with complete exclusion of bilateral subclavian artery aneurysms.
Fig 4. LSA techniques: subclavian-to-carotid transposition (left) and carotid-subclavian bypass with proximal ligation
of LSA (right).
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although scrutiny for wire breaks was not pursued with
intensity until the last 12 months of this experience. No
instance of migration or metal fractures was seen during the
relatively short follow-up herein reported. Four additional
mortalities were observed during follow-up, unrelated to
the endograft or aortic pathology in three cases and from
unknown causes in one case.
DISCUSSION
Several previous reports have shown the feasibility of
stent graft repair in the thoracic aorta.9-11 Dake and his
colleagues11,13,14 and Fann et al15 at Stanford have led the
way, accumulating one of the most impressive series. With
few exceptions, these efforts have focused on the treatment
of TAA and type B AD. The natural history of TAA is
similar to, if not worse than, that of AAA. The often-quoted
6-cm diameter threshold before consideration of elective
repair likely reflects surgeon reluctance to recommend tho-
racic aortic replacement because of risks of serious morbid-
ity and mortality. A diameter of more than 5.0 cm, or twice
the size of an adjacent nonaneurysmal segment of aorta,
may be a more logical view. However, such statement is not
based on available evidence. Endovascular exclusion of
TAA can be a straightforward procedure both in concept
and technical execution, especially for those aneurysms that
begin more than 2 cm distal to the LSA. Aneurysm involve-
ment of the parasubclavian aorta (Figs 7 and 8) or extension
into the arch itself offer a greater technical challenge.
“Lengthening the branchless DTA” is an effective strategy
to expand applicability of stent graft repair with endograft
attachment as proximal as the left common carotid artery
and even up to the innominate artery. Coverage of the
origin of the LSA has been reported to be apparently safe,16
and our own experience with five such cases supports this
view.17 However, caution should be exercised and, at a
minimum, angiographic patency of the contralateral verte-
bral artery should be ascertained beforehand. Should ver-
tebrobasilar or arm ischemia develop after stent graft place-
ment, it would be fairly simple to undertake secondary
revascularization with cervical transposition or bypass. An-
eurysmal involvement or close proximity to the LSA, on the
other hand, poses a different kind of concern related to the
Fig 5. A, Large aneurysm at site of previous surgical repair of thoracic aortic coarctation (left). Endograft repair
(right) with coverage of LSA and left common carotid artery. Preliminary transposition/revascularization involved
carotid-to-carotid bypass (circle) and left carotid-subclavian bypass (arrow). B, Adjunctive technique to enable
endograft placement up to origin of innominate artery. Left, Carotid-to-carotid bypass, left carotid-subclavian bypass,
proximal ligation of left common carotid and LSA. Right, femoroaxillary bypass, left subclavian-to-carotid transposi-
tion, proximal ligation of left common carotid artery.
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potential for reflux endoleak. Preliminary transposition of
the LSA is the preferred strategy for such cases. Complete
extrathoracic “debranching” of the arch is possible through
the type of extranatomic bypass configurations illustrated in
Fig 6. The “aortic arch map” (Fig 2), as proposed by Prof
Ishimaru (Tokyo, Japan; personal communication, January
2002) to document the site of proximal endograft attach-
ment within the aortic arch, is an important development
that may well become a reporting standard in the future.
Acute AD is a potentially catastrophic condition, quite
distinct from aneurysmal disease. A management consensus
of sorts has evolved where type B dissections are treated
medically—in the absence of imperatives for interven-
tion.11 The latter would include continued severe pain,
acute aneurysmal expansion of the false lumen, rupture,
and visceral-branch or leg ischemia. Surgical treatment
consists of graft replacement of the segment containing the
entry point to redirect blood flow exclusively down the true
lumen. Surgeons (and referring physicians alike) are reluc-
tant to recommend an aggressive management strategy
because of the high rates of serious perioperative complica-
tions and even mortality.11 Endovascular repair represents a
more appealing, less invasive approach, but significant
questions remain concerning indications and best strategy.
It would seem that, in the absence of imperatives (as
defined previously), it may be prudent to reserve stent graft
intervention for patients with significant aneurysmal dilata-
tion, imminent rupture, aortic-branch or distal ischemia, or
“failure of medical treatment.” Compression of the true
lumen (by the false lumen), as assessed with CT imaging,
may be a good predictor of ischemic complications and the
need for intervention.
In conclusion, we believe the following observations
are warranted on the basis of the clinical experience herein
reported: 1, stent graft repair of TAA and entry-site type B
AD is feasible and can be achieved with acceptable technical
success; 2, perioperative morbidity and mortality would
seem to compare favorably with historic surgical results; 3,
Fig 8. Talent stent graft exclusion of another large juxtasubcla-
vian thoracic pseudoaneurysm, with transsubclavian placement of
proximal bare spring.
Fig 6. Extrathoracic debranching of aortic arch with right femo-
roaxillary bypass, right subclavian-to-carotid transposition, carot-
id-to-carotid bypass, left carotid-subclavian bypass, proximal liga-
tion of right and left common carotid and LSA.
Fig 7. Large juxtasubclavian aneurysm involving proximal-most
portion of DTA.
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the Talent customized device proved versatile for endovas-
cular exclusion in a variety of morphologies, and improve-
ments in the delivery system are needed to optimize tech-
nical performance and deployment in the area of the aortic
arch and proximal DTA; 4, stent graft applicability can be
expanded through adjunctive surgical techniques designed
to transpose arch branches to “lengthen” the DTA; 5,
clinical indications remain unclear, especially for treatment
of AD; and 6, little is known about long-term durability of
either the device or the repair after thoracic aortic place-
ment.
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DISCUSSION
Dr Larry H. Hollier (New York, NY). I would like to
congratulate Dr Criado and his coauthors for a timely and well-
written paper. They clearly document the feasibility of thoracic
aneurysm repair using endografts with a 4.2% operative and aneu-
rysm-related mortality rate. While those results are encouraging,
they also identify specific problems with thoracic endografting and
raise additional questions regarding patient selection and physical
characteristics of endografts.
In our own experience with 68 thoracic endografts at Mount
Sinai, we noted many of the same problems identified by the
authors. Dr Criado reported a 12.8% incidence of the need for an
iliac conduit for device access. In our experience, if we include
those who had the iliac access added and those who had previous
aortofemoral or aortoiliac bypasses, then over a third of our pa-
tients needed a larger access vessel through which to introduce the
device. Since the 44-mm Talent requires at least a 24F sheath for
delivery, you can understand the importance of adequate size
vessels for access. And he indicated, the delivery system size for
thoracic endografts needs to be reduced. I would like to ask, first of
all, how many of your patients had prior aortic graft placed that you
could use for access?
In the series presented today, the authors noted that they
rejected 24% of the patients that were originally considered for
thoracic endografts. It would be helpful for you to share with us
the reasons for the exclusion of these patients. Was it the extent of
the aneurysm, the location of the aneurysm, either at the arch or at
the visceral area, or was it an access problem?
The authors report one access failure and abortion of the
procedure and another access problem from which they recovered.
We have had to abort procedures twice, once when we could not
make the device track around a very sharply angled aorta and
another because the tortuosity of the thoracic aorta itself caused
kinking of the device and we simply could not retract the sheath to
deploy the device. This was a particular problem. And in at least
two other cases, we had such difficulty deploying it that we had to
actually split the sheath and pull it out in pieces because it was
stretching to such an extent that it overrode the pusher rod. I
would like your comments about those types of deployment prob-
lems. When you talk about the reason for the access failure, was it
actually access failure or deployment failure?
You reported no incidence of neurologic deficit in your series,
which is certainly commendable. In our own patients, we had a 4%
incidence of neurologic deficit; no acute, all delayed. In each case,
the patient had a previous or concomitant placement of an abdom-
inal aortic graft as well as extensive coverage of the thoracic aorta.
Over two thirds of our patients required two to five stent grafts to
actually effect coverage of our aneurysms. Could you give us more
information regarding your patient demographics on this? For
example, how many patients had prior abdominal aortic grafts and
extensive coverage?
In the Stanford series, they also noted prior or concomitant
aortic grafting as a major associated risk factor for neurologic
deficit. In some reports, when one looks at patients who under-
went previous abdominal grafting and then had extensive coverage
of the thoracic aorta, the neurologic deficit rate rises to 10%.
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In our thoracic patients, we have seen a stent fracture in two
devices, one in the Talent and one in the Gore Thoracic Excluder.
A subsequent review by Gore noted fracture in one third of the
thoracic devices that had been implanted for 1 year or more. Have
you noted any late stent fractures, and how do you go about
looking for this? With some of the devices, it is very hard to identify
thoracic stent fractures. Interestingly, they do seem to be much
more common in the sigmoid-shaped thoracic aorta where you
actually have a lot of flexion occurring during the pulsations of the
aorta.
And finally, for your 16 patients with type B dissections, you
stated, I believe, that you only covered the entry site even in the
nonacute dissections. Mike Dake and his colleagues at Stanford, as
well as in our experience, we have noted that covering only the
entry site did not result in successful long-term sealing of the
secondary lumen. Although we get early closure of the false lumen,
they seem to reopen later requiring coverage of the entire extent.
What is the extent of your follow-up on these dissections, particu-
larly the chronic dissections?
In summary, I found this to be a great paper that suggests a
higher incidence of thoracic aortic pathology than I think has been
previously recognized by vascular surgeons and certainly a higher
incidence than recognized by industry. It also points out that
endografting for thoracic aneurysms is not as easy, nor necessarily
as efficacious, as initially imagined. In view of an increasing recog-
nition of late failure of thoracic devices, I think further technologic
improvements are clearly needed.
I enjoyed your excellent paper.
Dr Frank J. Criado. Thank you very much, Dr Hollier. We
and many others look upon you and Mount Sinai as one of the
leading centers in this particular area. The first question related to
the number of patients with prior AAA repair; we only had two but
did not use the abdominal graft as access site for the TAA endograft
in either. This issue also ties in with question 4 concerning spinal
cord ischemia. I suppose the fact that only two of our patients had
had the infrarenal aorta replaced contributed to the zero incidence
of paraplegia in this experience.
You also asked about the total number of referrals versus those
patients actually receiving an endograft. There were 15 patients
who were not accepted for stent graft repair, the reason being
inadequate access arteries in nine and extent of thoracic aortic
disease in six.
Your third question had to do with deployment issues. I
alluded to it in the presentation but only briefly. It is an important
aspect with the Talent device; the sheath we currently use (in the
United States) is somewhat inadequate, and significant difficulties
are encountered frequently at the time of device deployment across
the aortic arch. In spite of it, we have managed to deploy the device
successfully in every case where it was attempted. As you know, a
better delivery sheath has been developed, and we hope to have
regulatory approval to use it very soon.
Your next comment was about wire fractures. A handful of
these have been identified but none in our own experience. To my
knowledge, there have been no clinical consequences to date.
There is a larger body of information relating to the Talent AAA
device where several fractures have been identified; bending fatigue
has emerged as the most likely culprit, and corrective measures are
being implemented, mainly through metal surface enhancements.
The final comment, I believe, related to the 16 cases of aortic
dissection included in our report. Your observation was correct:
our strategy consisted of coverage of the entry site only, with a
minimum of 15-mm extension in either direction. I would agree
such strategy is in need of validation, and we may well have to revise
these concepts in the future if it becomes evident that endograft
coverage of a much longer segment is necessary to achieve stability
over the long haul.
Dr Bruce J. Brener (Millburn, NJ). What is the regulatory
status of these devices? What is the concept of compassionate
release? The companies are not particularly excited about compas-
sionate release of their products. How does a surgeon get access to
a thoracic device?
Dr Criado. The regulatory issues surrounding thoracic stent
grafting are significant indeed. Medtronic is planning to pursue a
pivotal clinical trial of their thoracic Talent stent graft this year. The
Medtronic Talent device happens to be the only commercially
produced thoracic endograft available in the United States at this
time. There are essentially two possible mechanisms for regulatory
access today. The first is “compassionate use,” whether emergent
or nonemergent. Of course, you can only do this if the manufac-
turer supports such efforts, and Institutional Review Board ap-
proval is obviously required. The second can be achieved through
the pursuit of an investigator (or “physician”)-sponsored IDE
(Investigational Device Exemption). The latter is very much fa-
vored by the FDA when done within the right context and putting
together a reasonable protocol and plan of action.
Dr Jens Jorgensen (Portland, Me). In the patients with
dissections, oftentimes there are issues with distal ischemia, either
visceral ischemia or lower extremity ischemia. And I did not
remember you addressing it on the paper. Did you treat them
operatively?
And I would just ask your opinion on what the role is for either
percutaneous fenestration or open stenting.
Dr Criado. All dissection cases included in the report were
either acute or subacute, and there was no need to do any such
procedures for aortic branch revascularization. The role of fenes-
tration and other catheter-based interventions is fairly well estab-
lished in the literature, but the context may be different. Our aim
has been, almost exclusively, to redirect blood flow down the true
lumen.
Dr Michael Golden (Philadelphia, Pa). You had mentioned
that it was your feeling that you did not need to do a subclavian
transposition in terms of distal ischemia. The question is, if you did
not operate on it open, would it be reasonable to put a blocker in
or to coil embolize the subclavian in order to prevent feeding of the
aneurysm sac or to just leave it alone?
Dr Criado. I think that may be a good idea indeed. That is,
placement of the endograft across the subclavian artery and then
coil embolize the proximal subclavian via a retrograde transbrachial
approach. We will probably test it soon!
Dr Golden. Right. But what I am saying is if you are covering
it, why do you not then also coil embolize or do something like
that?
Dr Criado. We have not done that.
Dr Ronald L. Nath (Medford, Mass). What is your experi-
ence with thoracic covered stent grafts for nonaneurysmal indica-
tions, such as “shaggy aorta” with distal embolization?
Dr Criado. We have had experience with three or four such
cases, and I feel endografting constitutes an excellent strategy
indeed.
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